Salzburg

• PIONEER TEENS. A research study to compare a new medicine oral semaglutide to a dummy medicine in children and teenagers with type 2 diabete … Ended
  2023-506923-27-00 5 2020-10-30 Type 2 diabetes
• A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment. Ended
  2023-506435-15-00 3 2020-08-25 Prostate cancer
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• CIRCULATE Ended
  2023-506715-18-00 5 2019-12-04 colon cancer stage II, rectal cancer stage II
• Nivo versus Nivo/Ipi or versus other chemotherapies to treat colorectal cancer Ended
  2023-503956-29-00 5 2019-08-26 Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient M
• Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma Ended
  2023-508343-48-00 5 2019-01-25 Adult patients with relapsed or refractory aggressive B-cell non-Hodgk
• Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended
  2022-502936-38-00 5 2019-01-09 Moderate and Severe Atopic Dermatitis
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended
  2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• Effect of ALlopurinol in addition to hypothermia for hypoxicischemic Brain Injury on Neurocognitive Outcome Ended
  2024-511322-31-00 5 2018-03-26 Brain injury termed “hypoxic-ischemic encephalopathy” (HIE) as a resul
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• HD21 Ended
  2024-518022-33-00 5 2016-07-15 Advanced Stage of Hodgkin Lymphoma
• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat … Ended
  2024-514808-13-00 5 2015-03-06 Localised prostate cancer at high risk of recurrence
• A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Ref … Ended
  2023-509472-42-00 5 Relapsed and/or Refractory Multiple Myeloma
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Clinical use of [18F]florastamine PET/CT in patients with PI-RADS≤3 report of multi-parametric MRI and suspected prostate cancer Ended
  2023-510421-14-00 5 Prostate cancer
• Rigosertib for RDEB-SCC Ended
  2024-518846-25-00 4 Recessive Dystrophic Epidermolysis bullosa associated Locally Advance

Showing 265–282 of 282 trials